Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06463873 · ClinicalTrials.gov registry record

Study of OmniGraft in Simultaneous Pancreas Kidney Recipients

A clinical trial, sponsored by University of Miami.

Terminated
Registry status
40
Enrollment target

NCT06463873: Clinical Trial study, sponsored by University of Miami.

NCT06463873 is a clinical trial that was terminated before completion, run by University of Miami. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06463873 was terminated before completion, sponsored by University of Miami.

TERMINATED
Registry status
40 participants
Enrollment target

Study Summary

The purpose of this research is learn about how OmniGraf works in kidney pancreas transplant patients. Also, to analyze the performance characteristics of OmniGrafTM (TruGraf Gene Expression Profiling (GEP) and T Cell Receptor Alpha Constant (TRAC) dd-cfDNA) in a population of simultaneous kidney pancreas transplants as a part of routine surveillance, as well as a part of the workup for patients clinically suspected to have rejection of the kidney and/or pancreas.

Primary Outcome

Number of participants that underwent SPK transplant measured by Omnigraft testing. The Omnigraft test includes TruGraf GEP and TRAC dd-cfDNA.

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2024-07-01
Est. Completion 2025-02-11
University of Miami

721 total trials

Why NCT06463873 stopped before completion

NCT06463873 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 40 participants, a relatively small participant target.

The record links to 0 conditions, and to 0 interventions.

NCT06463873 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT06463873 about?

NCT06463873 is a clinical study titled "Study of OmniGraft in Simultaneous Pancreas Kidney Recipients". The purpose of this research is learn about how OmniGraf works in kidney pancreas transplant patients. Also, to analyze the performance characteristics of OmniGrafTM (TruGraf Gene Expression Profiling (GEP) and T Cell Receptor Alpha Constant (TRAC) dd-cfDNA) in a population of simultaneous kidney pa...

What is the current status of trial NCT06463873?

This trial is currently terminated. The enrollment target is 40 participants. The study started on 2024-07-01. Estimated completion is 2025-02-11.

Who is sponsoring clinical trial NCT06463873?

This trial is sponsored by University of Miami, which has 721 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT01306019 · 40 participants · Phase 1

    Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)

  • NCT01608152 · 40 participants

    Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors

  • NCT01668082 · 40 participants · NA

    An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection

  • NCT02015013 · 40 participants · Phase 2

    Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06463873, the US trial registry maintained by the National Library of Medicine. NCT06463873 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.